-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Panaecin in Chronic Lung Infection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Panaecin in Chronic Lung Infection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Panaecin in Chronic Lung InfectionDrug Details:Panaecin (gallium citrate) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Panobacumab in Pseudomonas aeruginosa Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Panobacumab in Pseudomonas aeruginosa Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Panobacumab in Pseudomonas aeruginosa Pneumonia Drug Details: AR-101 (panobacumab, KBPA101)...
-
Product Insights
Ventilator Associated Pneumonia (VAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Ventilator Associated Pneumonia (VAP) Clinical Trials Market Report Overview The Ventilator Associated Pneumonia (VAP) clinical trial market research report provides an overview of Ventilator Associated Pneumonia Clinical trials scenario. This report provides top-line data relating to the clinical trials on Ventilator Associated Pneumonia. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Company Profile
Aridis Pharmaceuticals Inc – Company Profile
Aridis Pharmaceuticals Inc (Aridis) is a biopharmaceutical company. The company's pipeline products include AR-301 (tosatoxumab ), AR-320 (suvratoxumab), AR-501 (Gallium Citrate), AR-701 (COVID-19 mAb). AR-301 (tosatoxumab) is a Human anti-S. aureus mAb for therapeutic treatment of VAP, AR-320 (suvratoxumab) is a Long-acting human anti-S. aureus for prevention of VAP, AR-501 (Gallium Citrate) is a novel anti-infective for the growing problem of antibiotic resistance, AR-701 (COVID-19 mAb) Human mAb Cocktail to SARS-CoV-2 Virus. The company also works on macromolecular stabilization technology...
Add to Basket -
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
Net Present Value Model: Salvecin
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Salvecin Drug Details AR-301 (KBSA301) is...
-
Product Insights
Net Present Value Model: Panaecintm
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Panaecintm Drug Details Panaecin (gallium citrate) is...
-
Product Insights
Net Present Value Model: Suvratoxumab
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Suvratoxumab Drug Details Suvratoxumab (MEDI-4893) is...
-
Product Insights
Net Present Value Model: Aerumab
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Aerumab Drug Details AR-101 (panobacumab, KBPA101)...
-
Product Insights
Net Present Value Model: AR-712
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AR-712 Drug Details AR-712 is under...